Company intelligence / Profile preview

Yinuoke

Ownership: Private
Development stage: Other

Overview

YNK105 (R-ketorolac) has shown effectiveness in alleviating cachexia and increasing survival in tumor-bearing mice. In preclinical studies, cachectic mice achieved a 100% survival rate with a combination treatment of YNK105 and chemotherapy. The drug is currently in Phase I clinical trials for Cancer Anorexia-Cachexia Syndrome[2][3].

Therapeutic areas: Oncology
Modalities: Monoclonal antibodiesSmall molecules (R-ketorolac/YNK105)
Industry: Biotech

Drug pipeline

2 assets

YNK-101

IND

Indications: Cancer cachexia

1 more asset in the full pipeline.

Request access →

Partnerships

Harbour BioMed (strategic alliance for novel biologics in oncology)

Beyond the preview

Go deeper on Yinuoke.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yinuoke.

Explore the full profile